Generic Tirosint Availability
Last updated on Sep 11, 2024.
See also: Generic Tirosint-Sol
Tirosint is a brand name of levothyroxine, approved by the FDA in the following formulation(s):
TIROSINT (levothyroxine sodium - capsule;oral)
-
Manufacturer: IBSA
Approval date: October 13, 2006
Strength(s): 0.025MG [RLD], 0.05MG [RLD], 0.075MG [RLD], 0.1MG [RLD], 0.125MG [RLD], 0.15MG [RLD] -
Manufacturer: IBSA
Approval date: August 1, 2007
Strength(s): 0.013MG [RLD] -
Manufacturer: IBSA
Approval date: October 2, 2009
Strength(s): 0.088MG [RLD], 0.112MG [RLD], 0.137MG [RLD] -
Manufacturer: IBSA
Approval date: April 25, 2017
Strength(s): 0.175MG [RLD], 0.2MG [RLD] -
Manufacturer: IBSA
Approval date: June 22, 2022
Strength(s): 0.0375MG [RLD], 0.044MG [RLD], 0.0625MG [RLD]
Has a generic version of Tirosint been approved?
An Authorized Generic version of Tirosint has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- levothyroxine sodium ORAL CAPSULE 13 ug
Lannett Company, Inc.
NDC Code: 005274951 - levothyroxine sodium ORAL CAPSULE 25 ug
Lannett Company, Inc.
NDC Code: 005274952 - levothyroxine sodium ORAL CAPSULE 50 ug
Lannett Company, Inc.
NDC Code: 005274953 - levothyroxine sodium ORAL CAPSULE 75 ug
Lannett Company, Inc.
NDC Code: 005274954 - levothyroxine sodium ORAL CAPSULE 88 ug
Lannett Company, Inc.
NDC Code: 005274955 - levothyroxine sodium ORAL CAPSULE 100 ug
Lannett Company, Inc.
NDC Code: 005274956 - levothyroxine sodium ORAL CAPSULE 112 ug
Lannett Company, Inc.
NDC Code: 005274957 - levothyroxine sodium ORAL CAPSULE 125 ug
Lannett Company, Inc.
NDC Code: 005274958 - levothyroxine sodium ORAL CAPSULE 137 ug
Lannett Company, Inc.
NDC Code: 005274959 - levothyroxine sodium ORAL CAPSULE 150 ug
Lannett Company, Inc.
NDC Code: 005274960 - levothyroxine sodium ORAL CAPSULE 175 ug
Lannett Company, Inc.
NDC Code: 005274961 - levothyroxine sodium ORAL CAPSULE 200 ug
Lannett Company, Inc.
NDC Code: 005274962 - levothyroxine sodium ORAL CAPSULE 13 ug
YARAL Pharma Inc.
NDC Code: 823470005 - levothyroxine sodium ORAL CAPSULE 25 ug
YARAL Pharma Inc.
NDC Code: 823470010 - levothyroxine sodium ORAL CAPSULE 50 ug
YARAL Pharma Inc.
NDC Code: 823470015 - levothyroxine sodium ORAL CAPSULE 75 ug
YARAL Pharma Inc.
NDC Code: 823470020 - levothyroxine sodium ORAL CAPSULE 88 ug
YARAL Pharma Inc.
NDC Code: 823470025 - levothyroxine sodium ORAL CAPSULE 100 ug
YARAL Pharma Inc.
NDC Code: 823470030 - levothyroxine sodium ORAL CAPSULE 112 ug
YARAL Pharma Inc.
NDC Code: 823470035 - levothyroxine sodium ORAL CAPSULE 125 ug
YARAL Pharma Inc.
NDC Code: 823470040 - levothyroxine sodium ORAL CAPSULE 137 ug
YARAL Pharma Inc.
NDC Code: 823470045 - levothyroxine sodium ORAL CAPSULE 150 ug
YARAL Pharma Inc.
NDC Code: 823470050 - levothyroxine sodium ORAL CAPSULE 175 ug
YARAL Pharma Inc.
NDC Code: 823470055 - levothyroxine sodium ORAL CAPSULE 200 ug
YARAL Pharma Inc.
NDC Code: 823470060
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tirosint. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,691,411
Patent expiration dates:
- March 14, 2024✓
- March 14, 2024
-
Patent 7,723,390
Patent expiration dates:
- March 14, 2024✓
- March 14, 2024
More about Tirosint (levothyroxine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (139)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: thyroid drugs
- Breastfeeding
- En español
Patient resources
Other brands
Synthroid, Euthyrox, Levoxyl, Unithroid, ... +3 more
Professional resources
Other brands
Synthroid, Euthyrox, Levoxyl, Unithroid, ... +5 more
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.